electroCore (ECOR) FDA Approvals $4.79 -0.05 (-1.03%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$4.77 -0.02 (-0.44%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings electroCore's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by electroCore (ECOR). Over the past two years, electroCore has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as gammaCore. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. GammaCore nVNS FDA Regulatory Timeline and Events GammaCore nVNS is a drug developed by electroCore for the following indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - April 7,2026Enrollment Update Drug: gammaCore nVNSAnnounced Date: April 7, 2026Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society.AI SummaryelectroCore, Inc. announced enrollment of the first eight patients in a clinical study run by Acacia Clinics in collaboration with the Vagus Nerve Society. The trial will test electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for PTSD symptoms. Up to 40 adults will be treated over a 12-week period. The primary safety endpoint is treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in the PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is led by Danielle DeSouza, MSc, PhD, and Noah DeGaetano, MD. It is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The trial is expected to run about 10 months and aims to generate preliminary safety and effectiveness data to guide future research on nVNS for neuropsychiatric conditions.Read AnnouncementPublication - September 30,2025Publication Drug: gammaCore nVNSAnnounced Date: September 30, 2025Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI).AI SummaryelectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology showing that gammaCore® non-invasive vagus nerve stimulation (nVNS) can ease long-lasting symptoms after mild traumatic brain injury (mTBI). The study tested gammaCore alongside standard care and measured changes in patients’ post-concussion complaints. In an observational trial of 102 adults with persistent mTBI symptoms, researchers found significant improvements in 16 of 22 Neurobehavioral Symptom Inventory categories. Participants reported fewer headaches, less dizziness, better concentration, and reduced depression. About 34% said at least half of their symptoms meaningfully improved. Benefits appeared whether treatment began within three months of injury or more than a year later. No device-related adverse events occurred. Lead author Michael Ament, MD, noted this is the first larger prospective study suggesting that adding non-invasive vagus nerve stimulation to usual care may help people with ongoing mTBI symptoms.Read AnnouncementProvided Update - September 29,2025Provided Update Drug: gammaCore nVNSAnnounced Date: September 29, 2025Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium.AI SummaryelectroCore, Inc. announced that gammaCore™ Sapphire, its non-invasive vagus nerve stimulation device, has been added to a long-term reimbursement policy by Belgium’s National Institute for Health and Disability Insurance (RIZIV/INAMI). Effective October 1, 2025, the policy covers gammaCore Sapphire for patients suffering from cluster headaches. Coverage was granted based on strong clinical evidence of the therapy’s efficacy and cost-effectiveness, ensuring that more Belgian patients can access this treatment. Prof. Peter Paemeleire of Ghent University Hospital praised the decision, noting that non-invasive vagus nerve stimulation offers both clinical and economic benefits. He emphasized that wider reimbursement will help patients manage their daily lives more effectively while supporting a sustainable healthcare system. Silvert Medical, electroCore’s distribution partner in Belgium, played a key role in securing this reimbursement through its local expertise and provider relationships. “Securing long-term reimbursement in Belgium is a major milestone,” said Tanja Martin, Senior Director of Strategic Product Lifecycle at electroCore. This achievement sets the stage for expanding access to gammaCore™ Sapphire across Europe.Read Announcement electroCore FDA Events - Frequently Asked Questions Has electroCore received FDA approval? As of now, electroCore (ECOR) has not received any FDA approvals for its therapy in the last two years. What drugs has electroCore submitted to the FDA? In the past two years, electroCore (ECOR) has reported FDA regulatory activity for gammaCore nVNS. What is the most recent FDA event for electroCore? The most recent FDA-related event for electroCore occurred on April 7, 2026, involving gammaCore nVNS. The update was categorized as "Enrollment Update," with the company reporting: "electroCore, Inc. announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society." What conditions do electroCore's current drugs treat? Currently, electroCore has one therapy (gammaCore nVNS) targeting the following condition: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Innate Pharma FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies KORU Medical Systems FDA Events Apyx Medical FDA Events Microbot Medical FDA Events RenovoRx FDA Events Envoy Medical FDA Events Adagio Medical FDA Events Inspira Technologies OXY B.H.N. FDA Events Nyxoah FDA Events HeartBeam FDA Events Nano-X Imaging FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:ECOR last updated on 4/7/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding electroCore, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share electroCore With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - April 7,2026Enrollment Update Drug: gammaCore nVNSAnnounced Date: April 7, 2026Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society.AI SummaryelectroCore, Inc. announced enrollment of the first eight patients in a clinical study run by Acacia Clinics in collaboration with the Vagus Nerve Society. The trial will test electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for PTSD symptoms. Up to 40 adults will be treated over a 12-week period. The primary safety endpoint is treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in the PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is led by Danielle DeSouza, MSc, PhD, and Noah DeGaetano, MD. It is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The trial is expected to run about 10 months and aims to generate preliminary safety and effectiveness data to guide future research on nVNS for neuropsychiatric conditions.Read Announcement
Publication - September 30,2025Publication Drug: gammaCore nVNSAnnounced Date: September 30, 2025Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI).AI SummaryelectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology showing that gammaCore® non-invasive vagus nerve stimulation (nVNS) can ease long-lasting symptoms after mild traumatic brain injury (mTBI). The study tested gammaCore alongside standard care and measured changes in patients’ post-concussion complaints. In an observational trial of 102 adults with persistent mTBI symptoms, researchers found significant improvements in 16 of 22 Neurobehavioral Symptom Inventory categories. Participants reported fewer headaches, less dizziness, better concentration, and reduced depression. About 34% said at least half of their symptoms meaningfully improved. Benefits appeared whether treatment began within three months of injury or more than a year later. No device-related adverse events occurred. Lead author Michael Ament, MD, noted this is the first larger prospective study suggesting that adding non-invasive vagus nerve stimulation to usual care may help people with ongoing mTBI symptoms.Read Announcement
Provided Update - September 29,2025Provided Update Drug: gammaCore nVNSAnnounced Date: September 29, 2025Indication: Acute and preventive treatment of migraine in adolescents between 12 and 17 years of ageAnnouncementelectroCore, Inc. announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium.AI SummaryelectroCore, Inc. announced that gammaCore™ Sapphire, its non-invasive vagus nerve stimulation device, has been added to a long-term reimbursement policy by Belgium’s National Institute for Health and Disability Insurance (RIZIV/INAMI). Effective October 1, 2025, the policy covers gammaCore Sapphire for patients suffering from cluster headaches. Coverage was granted based on strong clinical evidence of the therapy’s efficacy and cost-effectiveness, ensuring that more Belgian patients can access this treatment. Prof. Peter Paemeleire of Ghent University Hospital praised the decision, noting that non-invasive vagus nerve stimulation offers both clinical and economic benefits. He emphasized that wider reimbursement will help patients manage their daily lives more effectively while supporting a sustainable healthcare system. Silvert Medical, electroCore’s distribution partner in Belgium, played a key role in securing this reimbursement through its local expertise and provider relationships. “Securing long-term reimbursement in Belgium is a major milestone,” said Tanja Martin, Senior Director of Strategic Product Lifecycle at electroCore. This achievement sets the stage for expanding access to gammaCore™ Sapphire across Europe.Read Announcement